| Document |
Document Title |
|
WO/2021/260519A1 |
The present invention provides new derivatives of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-
4,5,6,7-tetrahydro-1H-pyrazolo[3,4c] pyridine-3-carboxamide (Apixaban) able to increase its water solubility. These derivative...
|
|
WO/2021/261172A1 |
The present invention addresses the problem of providing a simple production method that can be industrially applied and that enables direct production of apixaban. Through usage of said simple production method, apixaban, which is the o...
|
|
WO/2021/262329A1 |
Provided are methods for clinical treatment of complement-associated conditions comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment t...
|
|
WO/2021/261712A1 |
The invention relates to hemoglobin derivative, particularly hemoglobin which is co-conjugated with both fatty acid-linked polyethylene glycol (FA-PEG) derivatives and alkoxy polyethylene glycol (alkoxy-PEG) derivatives, and a method for...
|
|
WO/2021/258160A1 |
The invention also relates to antigen binding proteins and related fragments thereof for binding Von Willebrand factor (VWF) and uses thereof. In one aspect, the present invention provides an antigen binding protein comprising an antigen...
|
|
WO/2021/262803A1 |
Pharmaceutical formulations to prevent or treat hemorrhagic shock are provided. The pharmaceutical formulations comprise an oxygenation complement comprising a hemoglobin-based oxygen carrier (HBOC) and blood plasma. Related methods to p...
|
|
WO/2021/261528A1 |
[Problem] To solve the problem of new COVID-19 pandemic by using Tinospora crispa or a plant analogous thereto. 1. Enhancement of recognition in countries other than the countries where Ayurveda is flourishing, for example, India, Pakist...
|
|
WO/2021/263070A1 |
The disclosed methods are generally directed to preventing, treating, suppressing, controlling or otherwise mitigating side effects of T-cell therapy, the T-cell therapy designed to accelerate immune reconstitution, induce a graft-versus...
|
|
WO/2021/261571A1 |
The present invention pertains to a vascular endothelial cell protecting agent, a blood-cerebrospinal fluid barrier protecting agent, and a central nervous system protecting agent, comprising at least one compound selected from the group...
|
|
WO/2021/257899A1 |
The present disclosure provides, inter alia, methods for treating hemophilia A as well as computer-based-systems, including software-based pharmacokinetics systems, and their use to determine dosing information for subjects who have hemo...
|
|
WO/2021/257353A1 |
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit...
|
|
WO/2021/257668A1 |
Provided herein are compositions useful for co-administering with a gene therapy vector to a patient having pre-existing neutralizing antibodies to the viral source of the gene therapy vector capsid. The compositions comprise an FcRn lig...
|
|
WO/2021/255159A1 |
The present disclosure relates to an immediate release tablet of daprodustat having good tensile strength. In other aspects, medical uses of the immediate release tablet and dosage regimens for using the immediate release tablet are disc...
|
|
WO/2021/257800A1 |
Provided herein are methods for reducing, minimizing, or controlling drug-drug interactions resulting from administration of a first drug that is vadadustat (i.e., {[5-(3- chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Com...
|
|
WO/2021/257356A1 |
The present disclosure relates kits and methods for measuring the potency of an andexanet sample in neutralizing a factor Xa inhibitor and restoring the activity of a wild-type factor Xa.
|
|
WO/2021/253695A1 |
Provided is a thrombin from reptiles, which is obtained by means of the following method: using a gene cloning method to obtain a sequence of Gekko japonicus Prethrombin-2; constructing a Prethrombin-2 eukaryotic expression recombinant p...
|
|
WO/2021/253662A1 |
Provided is a nanobody for resisting an FXII specific region or an antigen binding fragment thereof. The nanobody or the antigen binding fragment thereof is combined with FXII by means of a binding epitope of FXII to block the activation...
|
|
WO/2021/257532A1 |
Provided herein are methods of treating anemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an ALK2 inhibitor.
|
|
WO/2021/255438A1 |
The present invention relates to a novel therapeutic combination for the prevention/treatment of acute respiratory distress syndrome (ARDS), particularly in patients suffering with respiratory tract infections (e.g. COVID-19).
|
|
WO/2021/253067A1 |
The invention relates to the treatment of thromboembolic conditions, to fibrin clot formation and related thrombin activity, and to preparation of compounds, in particular, peptides and polypeptides for inhibiting, or for modifying the c...
|
|
WO/2021/250026A1 |
The present invention relates to an isolated protein binding to human Glycoprotein VI (hGPVI) for treating or preventing an acute respiratory distress syndrome (ARDS), in particular a SARS-CoV-2-related ARDS.
|
|
WO/2021/251450A1 |
A medicine for treating or preventing porphyria, which contains, as an active ingredient, 1-\{2-[(3S,4R)-1-\{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-meth
oxyphenyl)pyrrolidin-3-yl]carbonyl\}-4-(methoxymethyl)pyrrol
idin-3-yl]-5-(trifluorome...
|
|
WO/2021/251908A1 |
There is provided a method of identifying a neutrophil progenitor, the method comprising: determining an expression of at least one biomarker selected from the group consisting of: CD71, LOX-1, CD164, CD112, CD181, TACSTD2, CD11b and CD4...
|
|
WO/2021/252761A2 |
Disclosed herein are monomeric and oligomeric compound embodiments for use as contraceptive agents. Monomeric compound embodiments disclosed herein comprise substituents that facilitate the ability of the compounds to exhibit progestogen...
|
|
WO/2021/251438A1 |
The present invention relates to a fusion protein including an erythropoietin polypeptide fused to the Fc region of IgG derived from a mammal (elsewhere also referred to as an EPO-Fc fusion protein). The erythropoietin polypeptide has an...
|
|
WO/2021/250624A1 |
The present invention relates to a novel crystalline compound of Vadadustat, to processes for its preparation, to pharmaceutical compositions containing it and to its use in therapy.
|
|
WO/2021/251337A1 |
CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compo...
|
|
WO/2021/249974A1 |
There is a dire need for innovative nanomedicine-based solutions for safe and efficient thrombolysis with a non-toxic, biocompatible, and biodegradable thrombus-targeted carrier. In the present invention, polysaccharide hydrogel submicro...
|
|
WO/2021/247748A1 |
Disclosed herein are lH-indole-7-carboxamide derivatives as protein kinase inhibitors, in particular Bruton's tyrosine kinase (BTK) inhibitors, pharmaceutical compositions comprising them, processes for preparing them and uses of such pr...
|
|
WO/2021/243396A1 |
The present application is directed to treating diseases associated with a coronavirus infection, specifically SARS-CoV-2 (COVID-19) in a human subject by administering an effective amount of a CD14 antagonist antibody. The present appli...
|
|
WO/2021/246966A1 |
The present invention relates to a method of treating lymphedema comprising administering an effective amount of a composition to a patient in need thereof. The composition consisting essentially of cyclodextrin or a pharmaceutically acc...
|
|
WO/2021/242970A1 |
Provided herein are methods of enhancing mechanical thrombectomy during endovascular therapy for acute thrombosis using 3,3'-diindolylmethane.
|
|
WO/2021/243376A1 |
Embodiments of the disclosure include methods of inhibiting and/or reversing blood vessel degeneration in an individual by administering to the individual a therapeutically effective amount of a fibroblast cell population. In specific em...
|
|
WO/2021/242760A1 |
The present disclosure provides methods of treating a viral infection comprising administering a protease inhibitor, optionally conjointly with an anticoagulant therapy and/or antiviral agent.
|
|
WO/2021/240356A1 |
Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
|
|
WO/2021/240371A1 |
The current disclosure provides methods and compositions for treatment of SARS-CoV-2 infection and associated conditions, including COVID-19 Associated Coagulopathy. Certain aspects of the disclosure are directed to methods for treatment...
|
|
WO/2021/243284A1 |
Antibody formulations and methods of making and using such formulations are provided herein. The formulation can be for intravenous administration. In some embodiments, the formulation is for subcutaneous administration. In some embodime...
|
|
WO/2021/242258A1 |
The present disclosure generally relates to methods for treating homocystinuria and hyperhomocysteinemia patients with cystathionine-gamma-lyase (CGL) enzymes.
|
|
WO/2021/239905A1 |
The present invention relates to compounds for medical use in the treatment or in the prevention or in the diagnosis of arterial or venous thromboembolism.
|
|
WO/2021/242204A1 |
The present invention relates to the gel formulations obtained from the extracts of aerial parts of some Phlomis species (P. kurdica, P. russeliana, P. pungens or P. rigida ) and wound healing effects of the said gel formulations.
|
|
WO/2021/239809A1 |
The present invention relates to use of plasma exchange therapy using only albumin as replacement for treating Covid-19 patients.
|
|
WO/2021/234543A1 |
Provided herein are compounds, compositions and methods useful for inhibiting lactate dehydrogenase (LDH) activity and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to LDH activit...
|
|
WO/2021/234547A1 |
Provided herein are compounds, compositions and methods useful for inhibiting lactate dehydrogenase (LDH) activity and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to LDH activit...
|
|
WO/2021/233994A1 |
The present invention provides SOCE inhibitors that are useful as therapeutic agents in a variety of applications. The present invention also relates to pharmaceutical compositions, products and kits comprising such SOCE inhibitors, and ...
|
|
WO/2021/235023A1 |
To provide a protein having glucocerebrosidase activity and also having thermostability. The aforementioned problem is solved by a protein that is plant-derived, belongs to the glycoside hydrolase family 1 (GH1), and has glucocerebrosida...
|
|
WO/2021/235278A1 |
The present disclosure addresses the problem of providing a technique for improving at least the QOL of 40-year-old or older menopausal women without postmenopausal syndrome. The problem is solved by a QOL improving composition for 40-ye...
|
|
WO/2021/235532A1 |
A drug for enhancing the fibrinolytic system containing a compound represented by general formula (1) (in the formula, R1 represents a quinolyl group, R2 represents a halogen atom, and R3 represents a carboxy group or a biologically equi...
|
|
WO/2021/233432A1 |
A blood-purification molecular concentrate. The blood-purification molecular concentrate is a solid-state or liquid-state preparation, and contains a pH regulator and substances existing in a molecular form, wherein the pH regulator is o...
|
|
WO/2021/230317A1 |
The present invention provides a pharmaceutical composition containing oxygen-dissolved perfluorocarbon, for use in administering oxygen to a subject. The present invention also provides a perfluorocarbon-containing pharmaceutical compos...
|
|
WO/2021/228865A1 |
Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from inflammatory conditions associated with autoimmune dise...
|
